# PROFESSIONAL PHARMACOLOGY STUDY GUIDE: CARDIOVASCULAR & DIABETES
**Format:** Structured Clinical Data & Regulatory Guidelines
**Source Material:** Dr. James Lecture Series, FDA Labels, Clinical Guidelines

---

## I. COMPARATIVE PHARMACOLOGY & EFFICACY

### 1. Renin-Angiotensin-Aldosterone System (RAAS) Inhibitors
| Feature | **ACE Inhibitors** (Lisinopril) | **ARBs** (Losartan) |
| :--- | :--- | :--- |
| **Mechanism** | Inhibits Angiotensin-Converting Enzyme (ACE). Blocks conversion of Angiotensin I $ightarrow$ II. **Increases Bradykinin.** | Blocks Angiotensin II Type 1 (AT1) receptors directly. **No effect on Bradykinin.** |
| **Hemodynamic Effect** | Vasodilation (Arterial & Venous), $\downarrow$ Aldosterone, $\downarrow$ Preload/Afterload. | Vasodilation, $\downarrow$ Aldosterone, $\downarrow$ Peripheral Resistance. |
| **Key Adverse Effect** | **Dry Cough** (due to Bradykinin accumulation), Angioedema. | Dizziness, Hyperkalemia. **Lower risk of cough/angioedema.** |
| **Clinical Pearl** | First-line for HF/Post-MI. Switch to ARB if cough develops. | Alternative for ACE-intolerant patients. |

### 2. Statin Intensity & Efficacy (LDL Reduction)
*   **High Intensity** ($\ge$ 50% LDL Reduction): Atorvastatin 40-80mg, Rosuvastatin 20-40mg.
*   **Moderate Intensity** (30-49% LDL Reduction): Atorvastatin 10-20mg, Simvastatin 20-40mg.
*   **Low Intensity** (<30% LDL Reduction): Simvastatin 10mg, Pravastatin 10-20mg.

---

## II. CARDIOVASCULAR DRUG MONOGRAPHS

### A. HMG-CoA Reductase Inhibitors (Statins)
*   **Drug:** Atorvastatin (Lipitor)
*   **Measurable Outcome:** Lowers LDL by 30-50% depending on dose; reduces cardiovascular event risk.
*   **Mechanism:** Competitively inhibits HMG-CoA reductase (rate-limiting enzyme in cholesterol synthesis). Upregulates hepatic LDL receptors.
*   **Contraindications:** **Active Liver Disease**, Pregnancy (Category X), Breastfeeding.
*   **Adverse Effects:** **Myopathy/Rhabdomyolysis** (risk increased by drug interactions), Hepatotoxicity (Transaminitis).
*   **Interactions:** **CYP3A4 Inhibitors** (Grapefruit Juice, Erythromycin, Ketoconazole) $ightarrow$ Toxic levels. Warfarin $ightarrow$ Increased INR.
*   **Clinical Pearl:** Administer in the **evening** when endogenous cholesterol synthesis is highest. Monitor CK if muscle pain occurs.

### B. Cardiac Glycosides
*   **Drug:** Digoxin (Lanoxin)
*   **Mechanism:** Inhibits Na+/K+ ATPase pump $ightarrow$ $\uparrow$ Intracellular Ca++ $ightarrow$ **Positive Inotrope** (Force) / **Negative Chronotrope** (Rate).
*   **Therapeutic Range:** Narrow (**0.5 – 2.0 ng/mL**). Toxic > 2.4 ng/mL.
*   **Adverse Effects:** **Toxicity:** Visual halos (yellow/green), Nausea/Vomiting, Bradycardia, AV Block.
*   **Interactions:** **Hypokalemia** (often from Loop Diuretics) precipitates toxicity. Verapamil/Amiodarone increase levels.
*   **Nursing Action:** **Apical Pulse for 60 seconds**; hold if < 60 bpm. Monitor K+ levels strictly.
*   **Antidote:** Digoxin Immune Fab (Digibind).

### C. Anticoagulants (Vitamin K Antagonists)
*   **Drug:** Warfarin (Coumadin)
*   **Mechanism:** Inhibits synthesis of Vitamin K-dependent clotting factors (II, VII, IX, X, Protein C/S).
*   **Measurable Outcome:** Target **INR 2.0 – 3.0** (2.5 – 3.5 for mechanical valves).
*   **Black Box Warning:** **Major or Fatal Bleeding.**
*   **Interactions:** **"The G's"** (Garlic, Ginger, Ginkgo, Ginseng) $\uparrow$ bleeding. Vitamin K foods (Spinach, Kale) $\downarrow$ efficacy. Antibiotics often $\uparrow$ INR.
*   **Patient Education:** Maintain **consistent** Vitamin K intake (do not eliminate, do not binge). Use soft bristle toothbrush.
*   **Antidote:** **Phytonadione (Vitamin K)**.

---

## III. DIABETES DRUG MONOGRAPHS

### A. Biguanides
*   **Drug:** Metformin (Glucophage)
*   **Measurable Outcome:** Reduces HbA1c by **1.0 – 2.0%**.
*   **Mechanism:** $\downarrow$ Hepatic glucose production, $\downarrow$ Intestinal absorption, $\uparrow$ Insulin sensitivity.
*   **Black Box Warning:** **Lactic Acidosis** (Rare but fatal; risk $\uparrow$ with renal impairment, alcohol, contrast dye).
*   **Contraindications:** eGFR < 30 mL/min, Acute/Chronic Metabolic Acidosis.
*   **Nursing Action:** **HOLD 48 hours before and after** iodinated contrast media procedures to prevent acute renal failure/lactic acidosis.

### B. SGLT2 Inhibitors
*   **Drug:** Empagliflozin (Jardiance), Canagliflozin (Invokana)
*   **Measurable Outcome:** Reduces HbA1c by 0.7 – 1.0%. **Reduces Heart Failure hospitalizations by ~30%** (HFrEF).
*   **Mechanism:** Inhibits SGLT2 in proximal renal tubule $ightarrow$ blocks glucose reabsorption $ightarrow$ **Glucosuria**.
*   **Adverse Effects:** **Genital Mycotic Infections** (Yeast), UTIs, Osmotic Diuresis (Hypotension/Dehydration), Euglycemic DKA.
*   **Black Box (Canagliflozin):** Historical warning for lower limb amputation (removed in 2020 but caution remains for PVD patients).

### C. GLP-1 Receptor Agonists
*   **Drug:** Semaglutide (Ozempic/Wegovy), Liraglutide (Victoza)
*   **Measurable Outcome:** HbA1c reduction ~1.5%. **Weight loss of 5-15%** (high dose).
*   **Mechanism:** Incretin mimetic: $\uparrow$ Glucose-dependent insulin, $\downarrow$ Glucagon, slows gastric emptying (satiety).
*   **Black Box Warning:** Risk of **Thyroid C-Cell Tumors**. Contraindicated in Medullary Thyroid Carcinoma (MTC) or MEN 2 syndrome.
*   **Adverse Effects:** **Pancreatitis** (Severe epigastric pain radiating to back), Nausea/Vomiting.

### D. Insulins
*   **High-Alert Medication:** Standard concentration **U-100** (100 units/mL).
*   **Administration:**
    *   **IV:** **Regular Insulin ONLY** (for DKA/HHS).
    *   **Mixing:** "Clear before Cloudy" (Regular first, then NPH).
    *   **Sites:** Abdomen (fastest) > Arm > Thigh > Buttock. **Rotate sites** to prevent **Lipohypertrophy**.
*   **Hypoglycemia Protocol (15/15 Rule):**
    1.  If BG < 70 mg/dL: 15g Fast-Acting Carb (4oz Juice).
    2.  Wait 15 mins. Retest.
    3.  If still < 70, repeat.
    4.  If Unconscious: **Glucagon IM** or **D50W IV**.

---

## IV. CLINICAL VIGNETTES (CASE STUDIES)

### Case 1: The "Drying" Diuretic
**Scenario:** 78yo male on Furosemide (Lasix) 40mg IVP for Pulmonary Edema.
*   **Vitals:** BP 100/60, HR 98.
*   **Complaint:** "I hear a ringing sound" and "my legs feel weak."
*   **Analysis:**
    *   **Ringing (Tinnitus):** Sign of **Ototoxicity** (pushed too fast).
    *   **Weakness:** Sign of **Hypokalemia**.
*   **Action:** Stop infusion, check BMP (K+), assess hearing.

### Case 2: The "Masked" Hypoglycemia
**Scenario:** Type 1 Diabetic prescribed Propranolol (Inderal) for migraine prophylaxis.
*   **Risk:** Non-selective Beta-Blockers block $\beta_2$ receptors (glycogenolysis) and $\beta_1$ (tachycardia).
*   **Outcome:** Patient may become hypoglycemic **without** the warning sign of palpitations/tachycardia.
*   **Action:** Teach patient to rely on other signs (sweating/diaphoresis is *not* masked) and monitor CGM closely.

---

## V. REGULATORY COMPLIANCE & SAFETY

### 1. FDA MedWatch Reporting
Nurses should report **Serious Adverse Events** (SAEs) not listed in the labeling, including:
*   Death or Life-Threatening events.
*   Hospitalization (initial or prolonged).
*   Disability or Permanent Damage.
*   Congenital Anomaly/Birth Defect.
*   **Product Quality Problems:** Contamination, defective components, poor packaging/labeling.

### 2. Selected Black Box Warnings
*   **ACE Inhibitors/ARBs:** Fetal Toxicity (Pregnancy).
*   **Beta-Blockers:** Rebound Cardiac Excitation (Do not stop abruptly).
*   **Metformin:** Lactic Acidosis.
*   **Thiazolidinediones (Glitazones):** Congestive Heart Failure (fluid retention).
*   **Fluoroquinolones (Antibiotic):** Tendon Rupture.

---

## VI. TECHNICAL APPENDIX: DATA STRUCTURE

### JSON Schema for Drug Data
For developers integrating this content into `nursegame`, use the following schema:

```json
{
  "$schema": "http://json-schema.org/draft-07/schema#",
  "title": "DrugMonograph",
  "type": "object",
  "properties": {
    "genericName": { "type": "string" },
    "brandName": { "type": "string" },
    "class": { "type": "string" },
    "indications": { "type": "array", "items": { "type": "string" } },
    "mechanism": { "type": "string" },
    "pharmacokinetics": {
      "type": "object",
      "properties": {
        "onset": { "type": "string" },
        "peak": { "type": "string" },
        "duration": { "type": "string" }
      }
    },
    "blackBoxWarning": { "type": "string" },
    "adverseEffects": {
      "type": "object",
      "properties": {
        "common": { "type": "array", "items": { "type": "string" } },
        "lifeThreatening": { "type": "array", "items": { "type": "string" } }
      }
    },
    "nursingImplications": {
      "type": "object",
      "properties": {
        "assessments": { "type": "array", "items": { "type": "string" } },
        "labs": { "type": "array", "items": { "type": "string" } },
        "antidote": { "type": "string" }
      }
    }
  },
  "required": ["genericName", "class", "mechanism"]
}
```
